Sally Robertson
News Medical
Contact Sally
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Sally:
What are the Symptoms of Gingivitis?
Gingivitis refers to inflammation and irritation of the gums that surround our teeth. This article looks at the symptoms of this disease. → Read More
What are the Survival Rates for Lung Cancer?
In this article, we investigated the survival rates for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). → Read More
COVID vaccines deployed in US highly effective at reducing hospitalizations and deaths
Researchers in the United States have conducted a large-scale study showing that the two-dose regimen vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) appear to be highly effective and durable in reducing the risk of hospitalizations and deaths following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). → Read More
SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection
Researchers at the University of Oxford have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) is associated with a lower risk of several sequelae among those who experience breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). → Read More
Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques
Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. → Read More
A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2
Researchers in the United States have developed a cost-effective, high-throughput pipeline for identifying effective nanobodies that target and neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). → Read More
SARS-CoV-2 delta variant generates infections more quickly than previous strains
Researchers in the UK have conducted a study suggesting that the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is transmitted more quickly than previously circulating variants. → Read More
COVID-19's impact on excess mortality in 2020 varied widely across Europe
A team of researchers has demonstrated that the impact of the coronavirus disease 2019 (COVID-19) pandemic on excess mortality varied widely both between and within five European countries in 2020. → Read More
Scientists develop an extremely potent siRNA with broad activity against SARS-CoVs
Researchers in Germany have developed a promising approach to suppressing the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). → Read More
Novel proteomics approach predicts severe COVID-19 outcomes
Researchers in the United States, Canada, and the UK have developed a potential new approach to predicting severe and critical outcomes among patients with coronavirus disease 2019 (COVID-19). → Read More
COVID-19 lockdown restrictions may increase preterm stillbirths
Researchers in Australia have reported that pregnant women in Melbourne were more likely to have a preterm stillbirth during the period when coronavirus disease 2019 (COVID-19) lockdown restrictions were imposed on the city, than they were during the corresponding period one and two years prior. → Read More
Cysteamine inhibits SARS-CoV-2 variants of concern in vitro
Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). → Read More
Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice
Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). → Read More
What makes SARS-CoV-2 variants more virulent?
Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest. → Read More
Human coronavirus replicates in bats without using the spike protein
Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors. → Read More
Researchers model impact of changes in contact rate patterns on COVID-19 incidence in US
Researchers in the United States have studied changes in contact rate patterns in the United States over the course of the coronavirus disease 2019 (COVID-19) pandemic and modeled the impact that these changes have had on the incidence of cases across different age groups. → Read More
Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant
Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). → Read More
Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection
Researchers in the UK and Germany have provided evidence for a novel mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – binds to human host cells. → Read More
U.S. vaccination effort against COVID-19 needs intensifying, warn researchers
Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). → Read More
Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine
Researchers in Canada, Italy, and the United States have encouraged extending the interval time between two doses of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine among individuals who have not previously been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). → Read More